• Search History (Register)
  • MeSH Browser
  • [Clear]
    • Canada

Welcome to the international HTA database


Showing [3486 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Pharmacoeconomic review report. Somatropin (Genotropin - Pfizer Canada Inc.) indication: growth hormone deficiency in adults
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Clinical review report. Somatropin (Genotropin - Pfizer Canada Inc.) indication: growth hormone deficiency in adults
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Somatropin (Genotropin - Pfizer Canada Inc.) indication: long-term treatment of children who have growth failure due to an inadequate secretion of endogenous growth hormone
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Clinical review report. Somatropin (Genotropin - Pfizer Canada Inc.) indication: long-term treatment of children who have growth failure due to an inadequate secretion of endogenous growth hormone
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Pharmacoeconomic review report. Somatropin (Genotropin - Pfizer Canada Inc.) indication: long-term treatment of children who have growth failure due to an inadequate secretion of endogenous growth hormone
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Pharmacoeconomic review report. Somatropin (Genotropin - Pfizer Canada Inc.) indication: Turner syndrome
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Clinical review report. Somatropin (Genotropin - Pfizer Canada Inc.) indication: Turner syndrome
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Somatropin (Genotropin - Pfizer Canada Inc.) indication: Turner syndrome
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Pharmacoeconomic review report. Ocriplasmin (Jetrea - Alcon Canada Inc.) indication: symptomatic vitreomacular adhesion
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Clinical review report. Ocriplasmin (Jetrea - Alcon Canada Inc.) indication: symptomatic vitreomacular adhesion
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Ocriplasmin (Jetrea - Alcon Canada Inc.) indication: symptomatic vitreomacular adhesion
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Bolused (vice infused) tranexamic acid in adults experiencing hemorrhagic shock: safety, patient benefits, and guidelines
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Diabetes care for indigenous populations: a review of the clinical evidence and guidelines
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Oncotype DX in women and men with ER-positive, HER2-negative early stage breast cancer who are lymph node negative: a review of clinical effectiveness and guidelines
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Platelet rich plasma lumbar disc injections for lower back pain: clinical effectiveness, safety, and guidelines
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Hepatitis C polymorphism testing: a review of the clinical evidence
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Mobilization of adult inpatients in hospitals or long-term/chronic care facilities: benefits and harms, safety, and guidelines
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Endoscopic ultrasound for the diagnosis of disease and staging of cancers in adult patients with gastroenterological or oncological disease: guidelines
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Fall risk assessment in adult patients: comparative evidence and guidelines
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) The ABCD2 scoring system for transient ischemic attacks: a review of the diagnostic accuracy and predictive value
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Computed tomography scanners for patients in rural or remote locations: clinical and cost-effectiveness
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Plasma Vaporization of the Prostate for Treatment of Benign Prostatic Hypertrophy: A review of clinical and cost-effectiveness, and safety
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Ketamine for adult patients who have suffered painful and traumatic injuries: a Review of Clinical Effectiveness, Cost-Effectiveness, Safety and Guidelines
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Pharmacoeconomic review report. Ingenol mebutate (Picato LEO Pharma Inc.) indication: topical treatment of non-hyperkeratotic, non-hypertrophic actinic keratosis in adults
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Clinical review report. Ingenol mebutate (Picato LEO Pharma Inc.) indication: topical treatment of non-hyperkeratotic, non-hypertrophic actinic keratosis in adults
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Ingenol mebutate (Picato - LEO Pharma Inc.) indication: actinic keratosis
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Dutasteride and finasteride for men with benign prostatic hyperplasia: comparative clinical effectiveness and safety
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Mobile x-ray imaging versus fixed x-ray imaging in long-term care: clinical and cost-effectiveness
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Vancomycin-resistant enterococci isolation and screening strategies: clinical evidence and cost-effectiveness
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Alcohol with chlorhexidine hand sanitizers: clinical effectiveness and guidelines
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Long-term use of ranibizumab for the treatment of age-related macular degeneration: a review of the clinical and cost-effectiveness and guidelines
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Vitamin D testing for northern populations: clinical and cost-effectiveness and guidelines
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Nitroglycerin for the treatment of pulmonary edema following submersion: clinical effectiveness and guidelines
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Diagnostic computed tomography angiography for adult patients: safety
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Case management for vulnerable or homeless persons: clinical and cost-effectiveness, and guidelines
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Third-line pharmacotherapy for type 2 diabetes erratum
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Loop recorders to detect atrial arrhythmias in patients post-discharge who have had a cryptogenic stroke: a review of clinical and cost-effectiveness
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Disposable surgical gowns and wrappers: clinical and cost-effectiveness, and guidelines
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Bronchial thermoplasty for severe asthma: clinical and cost-effectiveness, and guidelines
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Conjugate pneumococcal vaccine (13-Valent) for immunocompromised populations: a review of the clinical evidence
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Apixaban and rivaroxaban for stroke prevention in atrial fibrillation: safety
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Tools assessing patient-reported outcome measures in cancer patients: accuracy and guidelines
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Vitamin supplementation for hospitalized adults: clinical evidence and guidelines
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Oral nutrition intake for the prevention of falls in older adults: clinical effectiveness and guidelines
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Post-surgical surveillance for surgical site infections: guidelines
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Extracorporeal photopheresis following bone marrow transplant: clinical effectiveness
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Population-based colorectal cancer screening: guidelines
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Antibacterial sutures for wound closure after surgery: update on clinical effectiveness and guidelines for use
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Fecal bacteriotherapy for adult patients with recurrent clostridium difficile infection: update of clinical, cost-effectiveness, and guidelines
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Cleaning wipes for prevention of C. difficile infection in the hospital setting: clinical effectiveness
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Suctioning for respiratory blockage: clinical effectiveness and guidelines
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Suspended ceiling lifts: safety
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) BMI reduction and chronic disease management: clinical evidence
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Providing rehabilitation services for seven days versus five days per week: clinical effectiveness and guidelines
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Aspirating versus not aspirating prior to injection of medication: comparative clinical evidence and guidelines
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Reprocessing of single use medical devices: effectiveness, safety, and guidelines
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Short-acting intramuscular olanzapine for acute agitation: clinical and cost - effectiveness and guidelines
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Re-treatment with direct acting antivirals for chronic hepatitis C genotype 1: emerging evidence of clinical effectiveness and safety
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Closed intensive care units: clinical and cost-effectiveness, safety, and guidelines
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Direct acting antivirals for chronic hepatitis C genotype 1 in select populations: emerging evidence of clinical effectiveness and safety
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Eplerenone (Inspra - Pfizer Canada Inc.) new indication: NYHA class II heart failure
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Mobile apps for improving health: clinical evidence
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Fall prevention strategies for adults in outpatient programs: clinical evidence and guidelines
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Equipment required for medication nebulization: safety and guidelines
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Tocilizumab (Actemra - Hoffmann-La Roche Limited) new indication: polyarticular juvenile idiopathic arthritis
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Personal protection for visitors to patients on airborne precautions: clinical effectiveness and guidelines
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Sterilization of gauze for surgical procedures: clinical effectiveness, harms, and guidelines
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Intra-aortic balloon pumps for cardiac conditions: guidelines
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Nebulizers for the methacholine challenge test: diagnostic accuracy and guidelines
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Golimumab (Simponi - Janssen Inc.) new indication: ulcerative colitis
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Rivaroxaban (Xarelto- Bayer Inc.) new Indication: pulmonary embolism
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Bivalirudin infusion following angioplasty: safety
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Appropriate use of hand-held wireless devices in healthcare settings: guidelines
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) High-fidelity simulation training for health care professionals: cost effectiveness and guidelines
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Aclidinium bromide (Tudorza Genuair - Almirall Canada Ltd.) indication: chronic obstructive pulmonary disease
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) KRAS testing for metastatic colorectal cancer using therascreen KRAS RGQ PCR kit
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Dehumidifiers for reduction of humidity in operating rooms: clinical effectiveness and guidelines
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Capnography and/or oximetry monitoring of patients using patient-controlled intravenous opioids: clinical and cost-effectiveness, safety, and guidelines
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Oral intake in critical care patients: guidelines and recommendations
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Balloon gastrostomy devices for adults: guidelines for replacement, maintenance, and training
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Electric shocks from conducted electric weapons: long-term clinical effects and guidelines for medical follow-up
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Fentanyl transdermal patches in palliative care: clinical effectiveness, safety, and guidelines
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Magnetic resonance imaging for patients with surgically implanted devices: safety and guidelines
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Rotigotine (Neupro - UCB Canada Inc.) indication: idiopathic Parkinson disease (early and advanced)
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) OnabotulinumtoxinA (Botox - Allergan Inc.) indication: chronic migraine
2014     Institut national d'excellence en sante et en services sociaux (INESSS) [Efficiency of the "housing first" approach for people who are homeless and living with mental illness or with disorders associated to psychoactive substances]
2014     Institut national d'excellence en sante et en services sociaux (INESSS) [Facility planning and infection prevention: sanitary facilities in specialized care rooms and cubicles]
2014     Institut national d'excellence en sante et en services sociaux (INESSS) [ETIAMEST I & II: Highlights]
2014     Institut national d'excellence en sante et en services sociaux (INESSS) [Judicious use of 14 laboratory tests]
2014     Institut national d'excellence en sante et en services sociaux (INESSS) [Management of the extravasation of antineoplastic agents]
2014     Institut national d'excellence en sante et en services sociaux (INESSS) [Real-time magnetic resonance imaging (MRI)-guided radiation therapy]
2014     Institut national d'excellence en sante et en services sociaux (INESSS) [Public policies for the coverage of continuous positive airway pressure devices for the treatment of obstructive sleep apnea]
2014     Institut national d'excellence en sante et en services sociaux (INESSS) [Efficacy of neglect interventions for Indigenous children, families and communities]
2014     Institut national d'excellence en sante et en services sociaux (INESSS) [Building planning and infection control: hand hygiene dispensers and individual bathrooms in residential and long-term care centres]
2014     Health Quality Ontario (HQO) Multiple intravenous infusions phases 2a and 2b: OHTAC recommendation
2014     Health Quality Ontario (HQO) Frequency of testing for dyslipidemia: a systematic review and budget impact analysis
2014     Health Quality Ontario (HQO) Frequency of testing for dyslipidemia: an evidence-based analysis
2014     Health Quality Ontario (HQO) Evaluation of a chronic disease management system for the treatment and management of diabetes in primary health care practices in Ontario: an observational study
2014     Health Quality Ontario (HQO) Multiple intravenous infusions phase 2a: Ontario survey
2014     Health Quality Ontario (HQO) Multiple intravenous infusions phase 2b: laboratory study